Literature DB >> 27529673

Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF.

Mar Puigdellívol1,2,3, Ana Saavedra1,2,3,4, Esther Pérez-Navarro1,2,3,4.   

Abstract

One of the main focuses in Huntington's disease (HD) research, as well as in most neurodegenerative diseases, is the development of new therapeutic strategies, as currently there is no treatment to delay or prevent the progression of the disease. Neuronal dysfunction and neuronal death in HD are caused by a combination of interrelated pathogenic processes that lead to motor, cognitive and psychiatric symptoms. Understanding how mutant huntingtin impacts on a plethora of cellular functions could help to identify new molecular targets. Although HD has been classically classified as a neurodegenerative disease affecting voluntary movement, lately cognitive dysfunction is receiving increased attention as it is very invalidating for patients. Thus, an ambitious goal in HD research is to find altered molecular mechanisms that contribute to cognitive decline. In this review, we have focused on those findings related to corticostriatal and hippocampal cognitive dysfunction in HD, as well as on the underlying molecular mechanisms, which constitute potential therapeutic targets. These include alterations in synaptic plasticity, transcriptional machinery and neurotrophic and neurotransmitter signaling.
© 2016 International Society of Neuropathology.

Entities:  

Keywords:  A2AR; GluN3A; Kalirin-7; PDEs; PKA; cGMP; nSOC; p75NTR

Mesh:

Substances:

Year:  2016        PMID: 27529673     DOI: 10.1111/bpa.12432

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  8 in total

1.  Cdk5 Contributes to Huntington's Disease Learning and Memory Deficits via Modulation of Brain Region-Specific Substrates.

Authors:  Elena Alvarez-Periel; Mar Puigdellívol; Verónica Brito; Florian Plattner; James A Bibb; Jordi Alberch; Silvia Ginés
Journal:  Mol Neurobiol       Date:  2017-12-29       Impact factor: 5.590

2.  Mutant Huntingtin Causes a Selective Decrease in the Expression of Synaptic Vesicle Protein 2C.

Authors:  Chaohua Peng; Gaochun Zhu; Xiangqian Liu; He Li
Journal:  Neurosci Bull       Date:  2018-04-30       Impact factor: 5.203

3.  Inhibition of DREAM-ATF6 interaction delays onset of cognition deficit in a mouse model of Huntington's disease.

Authors:  Alejandro López-Hurtado; Daniel F Burgos; Paz González; Xose M Dopazo; Valentina González; Alberto Rábano; Britt Mellström; Jose R Naranjo
Journal:  Mol Brain       Date:  2018-03-09       Impact factor: 4.041

4.  Functional analysis of brain derived neurotrophic factor (BDNF) in Huntington's disease.

Authors:  Zhike Zhou; Shanshan Zhong; Rongwei Zhang; Kexin Kang; Xiaoqian Zhang; Ying Xu; Chuansheng Zhao; Mei Zhao
Journal:  Aging (Albany NY)       Date:  2021-02-25       Impact factor: 5.682

5.  Isoform-Specific Reduction of the Basic Helix-Loop-Helix Transcription Factor TCF4 Levels in Huntington's Disease.

Authors:  Kaja Nurm; Mari Sepp; Carla Castany-Pladevall; Jordi Creus-Muncunill; Jürgen Tuvikene; Alex Sirp; Hanna Vihma; Derek J Blake; Esther Perez-Navarro; Tõnis Timmusk
Journal:  eNeuro       Date:  2021-10-14

Review 6.  Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases.

Authors:  Della Grace Thomas Parambi; Khalid Saad Alharbi; Rajesh Kumar; Seetha Harilal; Gaber El-Saber Batiha; Natália Cruz-Martins; Omnia Magdy; Arafa Musa; Dibya Sundar Panda; Bijo Mathew
Journal:  Mol Neurobiol       Date:  2021-10-15       Impact factor: 5.682

7.  Modulation of dopamine D1 receptors via histamine H3 receptors is a novel therapeutic target for Huntington's disease.

Authors:  David Moreno-Delgado; Mar Puigdellívol; Silvia Ginés; Peter J McCormick; Estefanía Moreno; Mar Rodríguez-Ruiz; Joaquín Botta; Paola Gasperini; Anna Chiarlone; Lesley A Howell; Marco Scarselli; Vicent Casadó; Antoni Cortés; Sergi Ferré; Manuel Guzmán; Carmen Lluís; Jordi Alberch; Enric I Canela
Journal:  Elife       Date:  2020-06-09       Impact factor: 8.140

8.  Neuron type-specific increase in lamin B1 contributes to nuclear dysfunction in Huntington's disease.

Authors:  Rafael Alcalá-Vida; Marta Garcia-Forn; Carla Castany-Pladevall; Jordi Creus-Muncunill; Yoko Ito; Enrique Blanco; Arantxa Golbano; Kilian Crespí-Vázquez; Aled Parry; Guy Slater; Shamith Samarajiwa; Sandra Peiró; Luciano Di Croce; Masashi Narita; Esther Pérez-Navarro
Journal:  EMBO Mol Med       Date:  2020-12-28       Impact factor: 14.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.